Among the registered clinical trials performed with DC-based anti-tumor vaccines, the most common approach relies on the use of ex vivo differentiated DCs from leukapheresis-isolated CD14+ monocytes (MoDCs), cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin 4 (IL-4) [10]. The gene discussed is CSF2; the disease is neoplasm.